Notable Labs Inc.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically … Read more
Notable Labs Inc. (NTBL) - Net Assets
Latest net assets as of June 2024: $7.19 Million USD
Based on the latest financial reports, Notable Labs Inc. (NTBL) has net assets worth $7.19 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.00 Million) and total liabilities ($3.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.19 Million |
| % of Total Assets | 65.3% |
| Annual Growth Rate | -19.52% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 130.15 |
Notable Labs Inc. - Net Assets Trend (2019–2023)
This chart illustrates how Notable Labs Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Notable Labs Inc. (2019–2023)
The table below shows the annual net assets of Notable Labs Inc. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $15.11 Million | +140.88% |
| 2022-12-31 | $-36.97 Million | +31.47% |
| 2021-12-31 | $-53.94 Million | -274.48% |
| 2020-12-31 | $30.92 Million | -14.17% |
| 2019-12-31 | $36.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Notable Labs Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12562000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $788.00K | 5.21% |
| Other Comprehensive Income | $110.00K | 0.73% |
| Other Components | $96.52 Million | 638.64% |
| Total Equity | $15.11 Million | 100.00% |
Notable Labs Inc. Competitors by Market Cap
The table below lists competitors of Notable Labs Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LIBERTY INT QVC-A (LB3A.SG)
STU:LB3A
|
$43.40K |
|
Ashtead Technology Holdings PLC
LSE:AT
|
$43.41K |
|
PRESS CORPORATION LIMITED
MSE:PCL
|
$43.42K |
|
BRIGHTSPIRE CAP. CL.A-01
F:41W0
|
$43.43K |
|
Won Tech Co. Ltd.
KO:336570
|
$43.36K |
|
Bonyf NV
PA:MLBON
|
$43.34K |
|
SUPERIOR PLUS
BE:8SP
|
$43.32K |
|
DAH SING FIN HLDGS
MU:DSR
|
$43.31K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Notable Labs Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -36,968,000 to 15,114,000, a change of 52,082,000.
- Net loss of 11,264,000 reduced equity.
- New share issuances of 3,983,000 increased equity.
- Other comprehensive income increased equity by 110,000.
- Other factors increased equity by 59,253,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.26 Million | -74.53% |
| Share Issuances | $3.98 Million | +26.35% |
| Other Comprehensive Income | $110.00K | +0.73% |
| Other Changes | $59.25 Million | +392.04% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Notable Labs Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $35.14 | $0.02 | x |
| 2020-12-31 | $24.78 | $0.02 | x |
| 2021-12-31 | $-31.19 | $0.02 | x |
| 2022-12-31 | $-16.68 | $0.02 | x |
| 2023-12-31 | $6.75 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Notable Labs Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3633.55%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.29x
- Recent ROE (-74.53%) is below the historical average (-41.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -53.84% | -3451.25% | 0.01x | 1.36x | $-23.00 Million |
| 2020 | -78.35% | -2627.44% | 0.02x | 1.35x | $-27.32 Million |
| 2021 | 0.00% | -5632.28% | 0.03x | 0.00x | $-10.66 Million |
| 2022 | 0.00% | -180087.50% | 0.00x | 0.00x | $-10.71 Million |
| 2023 | -74.53% | -3633.55% | 0.02x | 1.29x | $-12.78 Million |
Industry Comparison
This section compares Notable Labs Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Notable Labs Inc. (NTBL) | $7.19 Million | -53.84% | 0.53x | $43.38K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |